GE HEALTHCARE TECHNOLOGIES INC宣布，其创新锰基核磁共振造影剂的Lumina试验已进入II/III期临床阶段，首位患者完成给药。该项目获得美国食品药品监督管理局（FDA）快速通道资格认定，标志着公司新型影像剂研发管线取得重要进展。
此次突破性进展将加速推进该造影剂的临床开发进程。锰基造影剂作为新一代影像增强剂，有望为医学影像诊断领域带来革新。FDA快速通道资格将促进该药物与监管机构的密切沟通，并可能缩短审批时间。
GE医疗持续强化其在精准医疗领域的创新布局，通过推进新型影像剂研发管线，致力于为临床提供更安全、更有效的诊断解决方案。该里程碑事件进一步巩固了公司在医学影像创新领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.